Connect with us

Hi, what are you looking for?

Wednesday, May 31, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


MindBio Therapeutics receives approval for LSD study for major depression

The study has been approved by the Clinical Trials Registry

MindBio Therapeutics receives approval for take-home LSD microdosing trial
'We think our research into LSD microdosing is a game changer for mental health' says MindBio. Image via MindBio Therapeutics

Melbourne Australia’s MindBio Therapeutics Corp. (CSE: MBIO) (FSE: WF6) will be building upon positive results from an LSD study last year aimed at treating anxiety in a new take-home clinical trial on the psychedelic.

The company announced Wednesday that it had acquired ethics approval and assent for the new trial from the Clinical Trials Registry.

The study, which the company says is the first of its kind worldwide, will be examining the impact of microdosing LSD on 20 participants with Major Depressive Disorder (MDD) that will take the drug in the comfort of their own homes.

In the study, the feasibility and tolerability of an eight-week regimen of LSD microdosing will be assessed. The results derived from this trial will help to inform a significantly larger trial that will be conducted in the future.

The company’s study on the psychedelic last fall found that participants were more happy, energetic, creative and felt a higher overall level of wellness on the days they were dosed with LSD. MindBio recently published the results from that study in the journal Biological Psychiatry.

Read more: New survey aims to gather data on psychedelics use worldwide

Read more: LSD microdosing shows promise as treatment for major depression: MindBio study

MindBio went public and listed its shares on the Canadian Securities Exchange at the beginning of this month.

MindBio says over 260 million people worldwide are impacted by MDD and that the Centers for Disease Control and Prevention (CDC) estimate that 16 million American citizens struggle with depression every year. Therefore, new treatments are needed where others have been failing.

“We are pleased to be advancing our microdosing treatments to Phase 2 clinical trials. Psychedelic microdosing proposes to be a globally scalable solution to treating mental health conditions and we are excited by the data we are seeing and the potential future commercialization opportunities for these medicines,” said MindBio’s CEO Justin Hanka.

New York’s Mind Medicine Inc (NASDAQ: MNMD) (NEO: MMED) is another company actively studying LSD. Mind Medicine observed positive results from its recent study on the psychedelic in Switzerland, which showed that the drug helps alleviate anxiety and depression symptoms.  

MindBio’s stock dropped by 13.04 per cent Wednesday to $0.10 on the Canadian Securities Exchange.


Follow Mugglehead on Twitter

Follow Rowan Dunne on Twitter







Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


The Natural Medicine Health act will take effect on July 1


The group aims to foster EU-funded research on psychedelics and promote drug policies based on scientific evidence


The survey running until June 2 is sponsored by MAPS, Mind Medicine Australia, SABI Mind and Tiny


Research teams can receive up to $700K for an initial two-year phase to develop their studies, followed by up to $500K per year for...